GlaxoSmithKline makes vaccine executive changes

LONDON — British pharmaceutical company GlaxoSmithKline PLC on March 12 announced two changes in the executive lineup of its vaccines business.

Jean Stephenne was appointed chairman of GSK Biologicals. He will assume his new role immediately and continue in his current role as president of GSK Biologicals.

During the next two years, Glaxo said, operational responsibility will be taken over by Dr. Moncef Slaoui, who will also continue as chairman for research and development.

"Jean has built a world-leading vaccines business and as chairman will continue to be instrumental in driving forward our public health agenda," CEO Andrew Witty said.

"Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today. These changes will ensure continued strong focus on delivery and development of this pipeline."